GLP-1 Weight Loss —
The Right Medication for Your Body

Semaglutide was the medication that changed the conversation around obesity medicine. Originally developed to treat type 2 diabetes, it quickly became apparent that its effects on appetite, food intake, and body weight were remarkable — unlike anything seen from a non-surgical intervention before.

Semaglutide works by mimicking GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. By activating GLP-1 receptors in the brain, it sends a powerful satiety signal that reduces hunger, slows the rate at which your stomach empties, and decreases the reward response to food. Many patients describe it as the first time food simply stopped being on their mind.

In the landmark STEP trials, semaglutide produced an average of 14.9% body weight reduction over 68 weeks — results previously seen only with bariatric surgery. Beyond the scale, it has demonstrated meaningful improvements in blood sugar, blood pressure, triglycerides, and cardiovascular risk.

Tirzepatide represented a meaningful step forward in GLP-1 therapy by adding a second mechanism to the formula. Where semaglutide activates only the GLP-1 receptor, tirzepatide also activates the GIP receptor (glucose-dependent insulinotropic polypeptide) — a combination that produces synergistic metabolic effects greater than either pathway alone.

GIP is released from the small intestine in response to fat and carbohydrate intake. On its own, it has modest effects — but in combination with GLP-1 activation, it significantly amplifies insulin sensitivity, enhances fat metabolism, and may even improve the body's tolerance of GLP-1 receptor activity, reducing side effects while boosting efficacy.

In the SURMOUNT trials, tirzepatide produced an average weight loss of 20.9% at the highest dose over 72 weeks — surpassing every prior non-surgical weight loss intervention in clinical history at the time. Patients who had plateaued on semaglutide frequently see renewed progress when transitioning to tirzepatide.

Retatrutide is the newest and most powerful GLP medication in our arsenal. It activates three receptors simultaneously — GLP-1, GIP, and glucagon — making it the first triple agonist available and the most comprehensive metabolic intervention currently accessible outside of surgery.

The addition of glucagon receptor activation is what sets retatrutide apart from its predecessors. Glucagon is typically known as the counterpart to insulin — it signals the body to release stored energy. In the context of a GLP-1 medication, targeted glucagon receptor activation directly increases resting energy expenditure (how many calories you burn at rest) and actively mobilizes stored fat, including stubborn visceral and liver fat. This is a mechanism that semaglutide and tirzepatide simply don't have.

In Phase 2 clinical trials published in the New England Journal of Medicine, retatrutide produced an average of 17.5% body weight reduction at 24 weeks and up to 24.2% at 48 weeks — results that significantly surpassed prior GLP agents at equivalent time points. Beyond weight, it showed improvements in triglycerides, liver fat, blood pressure, and insulin resistance.